The Effect of Lansoprazole in Combination With Ecabet Sodium for Gastroesophageal Reflux Disease

Seoul National University

Status: Completed

Conditions: Gastroesophageal Reflux Disease

Treatments: Drug: ecabet sodium; Drug: placebo; Drug: lansoprazole

Study type: Interventional

Funder types: Other

Identifiers

NCT01039558

RECURRENT GERD

Details and patient eligibility

About

We will estimate the responses of lansoprazole and ecabet sodium combination therapy and compare with lansoprazole and placebo therapy in patients who need additional therapy after standard proton pump inhibitor treatment for 4week or more in recurrent gastroesophageal reflux disease.

Enrollment: 30 estimated patients

Sex: All

Ages: 19 to 75 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• age 19-75 years
• patients with typical gastroesophageal symptom or erosive reflux esophagitis on gastroduodenoscopy
• patients with recurrent gastroesophageal symptom after standard proton pump inhibitor treatment for 4 weeks or more

Exclusion criteria

• patients with gastric ulcer or duodenal ulcer
• patients with gastric cancer or esophageal cancer
• pregnant or postpartum women

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

30 participants in 2 patient groups, including a placebo group

lansoprazole + ecabet sodium

Active Comparator group

Treatment:

Drug: ecabet sodium

Drug: lansoprazole

lansoprazole + placebo

Placebo Comparator group

Treatment:

Drug: placebo

Drug: lansoprazole